Prognostic value of 68Ga PSMA I&T PET/CT SUV parameters on survival outcome in advanced prostat cancer

Basit Öğe Kaydı
dc.contributor.authorKomek, Halil
dc.contributor.authorCan, Canan
dc.contributor.authorYilmaz, Ugur
dc.contributor.authorAltindag, Serdar
dc.date.accessioned2024-04-24T16:02:43Z
dc.date.available2024-04-24T16:02:43Z
dc.date.issued2018
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectiveTo determine the association of 68Ga-PSMA-I&T PET/CT SUV parameters with survival outcome in advanced prostate cancer patients.MethodsA total of 148 consecutive patients mean age: 69.37.8years with advanced prostate cancer who underwent 68Ga-PSMA-I&T PET/CT were included in this retrospective study. Data on previous treatments, serum PSA levels (ng/mL), 68Ga-PSMA-I&T PET/CT findings metastases as well as survival data were recorded.ResultsMultivariate regression analysis revealed that Level 1 LN SUV/Liver SUV ratios>2.17 (OR 4.262; 95% CI 1.104-16.453, p=0.035), bone SUV>10.7(OR 23.650; 95% CI 4.056-137.888, p<0.001), bone SUV/spleen SUV ratio>1.842 (OR 25.324; 95% CI 4.204-152.552, p<0.001), highest SUVmax/liver SUV ratio>2.32 (OR 19.309; 95% CI 1.730-209.552, p=0.016) and highest SUVmax/spleen SUV ratio>1.842 (OR 22.354; 95% CI 2.637-189.493, p=0.004) were significant in the determination of increased mortality risk in advanced prostate cancer patients.Conclusion p id=Par4 Our findings, for the first time in literature, provided evidence on potential utility of tracer uptake (SUV) cut-off values on 68Ga-PSMA PET/CT in identification of the survival outcome of patients with metastatic disease and thereby in assisting in the selection of individualized therapeutic strategies tailored to the expected prognosis.en_US
dc.identifier.doi10.1007/s12149-018-1277-5
dc.identifier.endpage552en_US
dc.identifier.issn0914-7187
dc.identifier.issn1864-6433
dc.identifier.issue8en_US
dc.identifier.pmid30006752
dc.identifier.startpage542en_US
dc.identifier.urihttps://doi.org/10.1007/s12149-018-1277-5
dc.identifier.urihttps://hdl.handle.net/11468/14891
dc.identifier.volume32en_US
dc.identifier.wosWOS:000445732600005
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofAnnals of Nuclear Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectProstate Canceren_US
dc.subject68ga-Psma-I&T Peten_US
dc.subjectCten_US
dc.subjectMetastasisen_US
dc.subjectLymph Nodeen_US
dc.subjectBoneen_US
dc.subjectSuven_US
dc.titlePrognostic value of 68Ga PSMA I&T PET/CT SUV parameters on survival outcome in advanced prostat canceren_US
dc.titlePrognostic value of 68Ga PSMA I&T PET/CT SUV parameters on survival outcome in advanced prostat cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu